TREE NEWS update: China’s National Healthcare Security Administration on Nov. 14 added Jinbeixin (fuxinqibai monoclonal antibody), a Class 1 innovative biologic developed by GenSci, to the national medical insurance drug catalog. The drug, administered once every six months, is used to treat gout. The listing was part of the agency’s announcement of newly added drugs for both the national reimbursement list and the commercial insurance innovative drug list.
China’s NMPA adds GenSci’s gout drug Jinbeixin to national reimbursement list
AI take
The reimbursement listing matters less as a milestone for GenSci than as a signal about how China is routing innovative biologics into public coverage. A twice-yearly gout biologic entering the national catalog suggests payers are willing to absorb higher-cost chronic therapies where dosing frequency and adherence advantages are clear. The commercial insurance innovative drug list announced alongside it is worth watching as a parallel channel for products that don't clear the national bar.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
25m ago
China Securities Regulator Wu Qing Calls for Guarding Against AI Algorithm Black Boxes, Cyberattacks
27m ago
China Securities Regulator to Study Listing Rules for Large Tech Firms
28m ago
China Securities Regulatory Commission Chair Wu Qing Calls for Deeper Study of Market Stability Mechanisms
29m ago
China Securities Regulator to Review Quant Trading and Share Reduction Rules
56m ago
China Securities Association Launches Survey on Brokerage Financial Digitalization
2h ago
DHS Secretary Mullin: No Evidence Incident Was Cyberattack or AI-Caused